Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.49 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.48 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 4/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389589 | 0.91 | GPR119 (0.51) | GPR119LIMK2TBK1TGFBR1 | |
| SCHEMBL387040 | 0.90 | GPR119 (0.58) | GPR119LIMK2 | |
| SCHEMBL389354 | 0.90 | GPR119 (0.49) | GPR119LIMK2TBK1TGFBR1 | |
| SCHEMBL391170 | 0.89 | GPR119 (0.48) | GPR119LIMK2TBK1 | |
| SCHEMBL391594 | 0.89 | GPR119 (0.51) | GPR119LIMK2TBK1TGFBR1JAK2 | |
| SCHEMBL385723 | 0.89 | GPR119 (0.51) | GPR119LIMK2TBK1TGFBR1JAK2 | |
| SCHEMBL388932 | 0.88 | GPR119 (0.50) | GPR119LIMK2TBK1TGFBR1JAK2 | |
| SCHEMBL388222 | 0.85 | GPR119 (0.48) | GPR119LIMK2TBK1TGFBR1JAK2 | |
| SCHEMBL391745 | 0.85 | TBK1 (0.45) | GPR119LIMK2TBK1TGFBR1 | |
| SCHEMBL389675 | 0.84 | GPR119 (0.46) | GPR119LIMK2TBK1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036434-A1 | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036434-A1 | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP11B1 | GPR119 31/4885LIMK2 4556/4885TBK1 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.